INNOVENT BIO (01801) rose more than 5%, with the stock up 5.18% to HK$89.25 at the time of writing. Turnover reached HK$325 million. On April 30, the company announced that its product revenue for the first quarter of 2026 exceeded RMB 3.8 billion, representing a year-on-year increase of over 50%. This robust performance demonstrates the successful execution of the company's "dual-engine" growth strategy.

The company's leading position in oncology is becoming increasingly prominent, with five tyrosine kinase inhibitors (TKIs) achieving rapid sales growth following their recent inclusion in the National Reimbursement Drug List (NRDL). Additionally, the comprehensive product portfolio has emerged as a strong new driver of revenue growth, primarily due to the outstanding performance of core products such as Xermelo® (Masituotide Injection), Xinbile® (Toleximab Injection), and Xinbimin® (Tetoyou Monoclonal Antibody N01 Injection).

The announcement stated that INNOVENT BIO continues to advance global innovation, creating sustained upward growth potential for the company's value. The company is progressing three high-value potential molecules—IBI363 (a PD-1/IL-2α-biased bispecific antibody), IBI343 (a CLDN18.2 ADC), and IBI324 (a VEGF/ANG2 bispecific antibody)—into or towards global multi-center Phase III clinical studies. It is also continuing to invest in early-stage innovation to drive global clinical development for next-generation pipelines in oncology, cardiovascular and metabolic diseases (CVM), autoimmune disorders, and ophthalmology.